Sphingosine-1-phosphate (Sph-1-P) is a bioactive plasma lipid which affects cell proliferation and migration, etc., through 5 receptors: sphingosine-1-phosphate receptors 1 (S1P 1 ) to 5 (S1P 5 ).
7)
These results indicate that Sph-1-P caused bradycardia via S1P 3 in the heart, at least in the case of mice. On the other hand, i.v. administration of Sph-1-P at a low dose of 10 mg/kg provoked transient hypotension without affecting the heart rate in anesthetized rats. 6) In this case, it is expected that Sph-1-P caused vasodilation on the vascular endothelial cells via S1P 1 and S1P 3 , followed by activation of the endothelial isoform of nitric oxide synthase and NO production. [8] [9] [10] [11] We previously reported that a S1P 1 antagonist, designated as chemical lead 2, showed anti-angiogenesis activity in a rabbit cornea model and inhibition of the swelling of mouse feet in an anti-type II collagen antibody-induced arthritis model. 12 ) Afterwards, we synthesized derivatives of chemical lead 2 to obtain more effective S1P 1 antagonists and determined the representatives, named as compounds 1 to 5. The aim of this study is to elucidate whether the derivatives inhibit the effect of Sph-1-P both in vitro and in vivo. Therefore, here we describe the Sph-1-P antagonistic activity of the representative derivatives, compounds 1 to 5, through several in vitro and in vivo assays focusing on the proliferation, migration, tube formation, and relaxation of vascular endothelial cells. ® (thiobutabarbital sodium salt) was synthesized by Sankyo Co., Ltd. All other reagents were supplied by Sigma-Aldrich Japan (Tokyo, Japan) unless otherwise stated. Male Sprague-Dawley rats (250-300 g) were purchased from Japan SLC, Inc. (Shizuoka, Japan). The animals were maintained in a room controlled at a temperature and relative humidity of 24Ϯ2°C and 40-70%, respectively, and given food and water ad libitum. The experimental protocols were approved by the Ethics Review Committee for Animal Experimentation of Sankyo Co., Ltd.
MATERIALS AND METHODS

General Reagents and Animals
Primary Cells and Each Sph-1-P Receptor Expressing Cell Chinese hamster ovary (CHO) cells that stably express human S1P [1] [2] [3] [4] , namely CHO-S1P 1-4 , were established previously. [12] [13] [14] HUVEC were maintained with HuMedia-EG2 medium. CHO-S1P 1 cells were cultured with a-Minimum Essential Medium containing 10% (v/v) dialyzed fetal bovine serum (SAFC Biosciences, Lenexa, KS, U.S.A.), 100 units/ ml penicillin G sodium, 100 mg/ml streptomycin sulfate, and 125 nM methotrexate without ribonucleosides and deoxyribonucleosides. CHO-S1P 2-4 cells were maintained with F-12 medium containing 10% (v/v) fetal bovine serum, 100 units/ml penicillin G sodium, 100 mg/ml streptomycin sulfate, and 400 mg/ml G418.
For the measurement of S1P 1-4 signaling using a fluorometric imaging plate reader (FLIPR), CHO-S1P 1 -Gqi5 cells and CHO-S1P 4 -Gqi5 cells that contain Gqi5 chimeric G proteins were used instead of the original cells to enable the measurement of Ca 2ϩ signaling. 14) These cells were maintained in the suitable medium mentioned above with 200 mg/ml Hygromycin. For the measurement of S1P 2 and S1P 3 signaling, intact CHO-S1P 2 cells and CHO-S1P 3 cells were used, respectively.
Cyclic AMP (cAMP) Assay and [ 33 P]Sph-1-P/S1P 1 Binding Assay The cAMP assay and the binding assay using CHO-S1P 1 cells were performed as described previously. 12, 15) The 100 nM Sph-1-P was used as a stimulant in the cAMP assay. The specific activity of [ 33 P]Sph-1-P was 3400 cpm/fmol.
Sph-1-P Receptor Subtype Specificity of Compound 5
The receptor subtype specificity of compound 5 was determined with a FLIPR system according to our previous report. 14) For the measurement of Ca 2ϩ signaling in CHO-S1P 1-4 cells, 100 nM, 100 nM, 10 nM, and 10 mM Sph-1-P were used as a stimulant, respectively, according to each cellular reactivity. 16) HUVEC were suspended in HuMedia-EB2 medium containing 1% (v/v) fetal bovine serum, 1 mg/ml hydrocortisone, 50 mg/ml gentamycin, 50 ng/ml amphotericin B, and 10 mg/ml heparin; and then 2500 of the cells were added to 96-well plates and cultured overnight. Dimethyl sulfoxide or a serial concentration of compound 5 was mixed into each well (nϭ6), and the HUVEC were stimulated with vehicle [80% (v/v) ethanol] or 100 nM Sph-1-P for 24 h at 37°C in 5% CO 2 . Then, 0.5 mCi of [6- 3 H]thymidine (GE Healthcare Bio-Sciences KK, Tokyo, Japan) was added to each well, and the HUVEC were further incubated for 7 h at 37°C in 5% CO 2 . The cells were harvested onto Printed Filtermat A filtermats (WALLAC, Turku, Finland Proper, Finland) with a Mach II cell harvester (Tomtec Inc., Hamden, CT, U.S.A.). The remaining cells in each well were detouched with 100 ml of 0.25% (w/v) trypsin and reharvested onto the same filtermats. The radioactivity from the cells on the filtermats was measured with a BETA-PLATE (PerkinElmer Inc., Waltham, MA, U.S.A.).
HUVEC Migration Assay
The inhibitory effect of compound 5 in the HUVEC migration assay was evaluated as described previously.
15) The 100 nM Sph-1-P was used for a stimulant of migration.
Rac Activation Assay The activation state of Rac within Sph-1-P-stimulated HUVEC was examined using a Rac Activation Assay Kit (Upstate Biotechnology Inc., Charlottesville, VA, U.S.A.), following the instructions of the manufacturer. First, 1ϫ10 6 of HUVEC were seeded into 10 cm dishes with HuMedia-EG2 medium, cultured for 24 h at 37°C in 5% CO 2 , and starved overnight in serum-free medium (HuMedia-EB2 medium containing 1 mg/ml hydrocortisone, 50 mg/ml gentamycin, 50 ng/ml amphotericin B, and 10 mg/ml heparin). On the day of the assay, dimethyl sulfoxide or 7.1 mM of compound 5 was mixed into the dishes and the HUVEC were stimulated for just 3 min at room temperature with vehicle [80% (v/v) ethanol] or 10 nM Sph-1-P. All of the medium was removed, the HUVEC were lysed with 0.8 ml of the ice-cold 1ϫMLB which came with the kit, and were placed on ice. The lysates were collected, the debris was removed by centrifugation, and 700 ml of supernatant and 10 ml of the PAK-1 PBD agarose beads which came with the kit were mixed and rotated for 1 h at 4°C. The beads were washed 3 times with 0.5 ml of 1ϫMLB, resuspended in 40 ml of 2ϫLaemmli sample buffer (Bio-Rad Laboratories, Hercules, CA, U.S.A.) containing 5% (v/v) 2-mercaptoethanol, and boiled for 5 min. Each boiled sample containing 5.7 mg of protein was loaded on a polyacrylamide gel. The HUVEC lysate containing 3 mg of protein was also loaded as a positive control. The activated Rac (beads-bound Rac) and the total Rac in HUVEC lysate were detected by immunoblotting with the anti-Rac mouse monoclonal antibody which came with the kit.
HUVEC Tube Formation and Cytotoxicity Assay A tube formation assay was performed according to the method of Lee et al. with modification. 17) Cultured HUVEC were stripped by trypsinization, washed once, and resuspended with serum-free Medium 199. Then, 400 ml of 5ϫ10 cated concentration of compound 5 or dimethyl sulfoxide and 40 ml of AlamarBlue (BioSource, Camarillo, CA, U.S.A.) were added to each well (nϭ4) and mixed. One micromolar Sph-1-P or vehicle [80% (v/v) ethanol] was added and the 48-well plate was incubated for 3 h at 37°C in 5% CO 2 . The cultured medium and plate were used for the cytotoxicity and tube formation assays, respectively.
For the HUVEC cytotoxicity assay, 200 ml of each cultured medium was moved to a 96-well flat clear bottom plate, and the fluorescence intensity of the reduced AlamarBlue (excitation at 530 nm/emission at 590 nm) in each cultured medium was measured with an ARVO SX (WALLAC, Turku, Finland Proper, Finland) as the index of HUVEC metabolism.
The same 48-well plate was used for the evaluation of the HUVEC tube formation. The cells in each well were fixed with 3.7% (v/v) formalin/phosphate buffered saline and stained with Diff-Quik (Sysmex, Hyogo, Japan). Each well was photographed using ϫ400 magnification and the HUVEC tube length was quantified with Kurabo angiogenesis quantity software ver. 1.0 (Kurabo Industries Ltd., Japan).
Inhibitory Effect on the Sph-1-P-Induced Hypotension Male Sprague-Dawley rats were anesthetized by an intraperitoneally (i.p.) injection of Inactin ® at a dose of 100 mg/kg. A Millar Micro-Tip ® catheter (SPR-320, Millar Instruments Inc., Houston, TX, U.S.A.) was inserted via the left femoral artery. The right and left femoral veins were cannulated for the Sph-1-P administration and the tested compound administration, respectively. The systemic blood pressure and heart rate were measured with a pressure transducer (AP-641G, Nihon Kohden, Tokyo, Japan) and a cardiotachometer (AT-601G, Nihon Kohden), respectively, and recorded on a heatwriting oscillograph (RJG-4128, Nihon Kohden). After stabilization, Sph-1-P was injected at a dose of 10 mg/kg as a control response. Then, each compound was administered at a dose of 10 mg/kg and Sph-1-P trials were performed at 3, 6, 9, 12, 15, 20, 25, and 30 min after compound administration. All the drugs were dissolved in 0.9% (w/v) saline solution. The inhibition (%) of each compound against Sph-1-P-induced hypotension was calculated from the minimum blood pressure after each Sph-1-P trial and plotted. The average of minimum blood pressure in stable state was set at 100% inhibition, whereas the minimum blood pressure after control injection of Sph-1-P was set at 0% inhibition. One mouse was used for compound 2, and two mice were used for compounds 1, 3, 4, and 5, respectively. In the case of using a pertussis toxin (PTX), 10 mg/kg PTX was i.p. administered once a day 3 d before the test. For the measurement of dosedependency of compound 5, it was administered at a dose of 0.1, 1, or 10 mg/kg; and Sph-1-P trials were performed at 3, 6, 9, 12, 15, 20, 25, 30, 40, 50, and 60 min after compound administration (nϭ3).
Statistical Analysis The statistical significance of the differences between the mean values was calculated by a non-paired t-test. A p value of Ͻ0.05 was considered to be significant. The IC 50 values of compounds were estimated with Prism 4 software (GraphPad Software, Inc., La Jolla, CA, U.S.A.).
RESULTS
S1P 1 Antagonistic Activity of Compounds 1-5 and the
Sph-1-P Receptor Subtype Specificity of Compound 5
Compounds 1-5 are representative derivatives of a prototype S1P 1 antagonist, chemical lead 2. Therefore, we first checked the S1P 1 antagonistic activity of compounds 1-5 using CHO-S1P 1 cells. As shown in Table 1 , compounds 1-5 inhibited the intracellular cAMP concentration decrease induced by 100 nM Sph-1-P, and the IC 50 values were 200, 220, 54, 49, and 38 nM, respectively. The S1P 1 antagonistic activity of compound 5, which was the most potent inhibitor, was also measured in a 0.5 nM [
33 P]Sph-1-P/S1P 1 binding assay and the IC 50 value was 200 nM. Next, we examined the Sph-1-P receptor subtype specificity of compound 5 through the FLIPR system using CHO-S1P 1-4 cells. As shown in Table  2 , compound 5 was the S1P 1 -directional antagonist, although the antagonistic effect on other families of G protein-coupled receptor was not tested.
Inhibitory Effect of Compound 5 on Both the Proliferation and Migration of Sph-1-P-Stimulated HUVEC
In the process of angiogenesis, Sph-1-P is thought to promote the proliferation, migration, and tube formation of vascular endothelial cells and to contribute to the extension of new blood vessels. 3, 16, 17) HUVEC are convenient primary cells because Sph-1-P-stimulated HUVEC can reproduce all three steps necessary for angiogenesis, i.e., proliferation, migra- The IC 50 value was calculated from the inhibition (%) of cAMP concentration decrease in S1P 1 -expressing cells, which were stimulated with 100 nM of Sph-1-P. The IC 50 value was calculated from the inhibition (%) of the Ca 2ϩ signaling of each receptor, which was measured with a fluorometric imaging plate reader (FLIPR). For the measurement of Ca 2ϩ signaling in CHO-S1P 1-4 cells, the 100 nM, 100 nM, 10 nM, and 10 mM Sph-1-P were used as a stimulant, respectively, according to each cellular reactivity. -, no inhibition; n.t., not tested. tion, and tube formation. 16, 17) Moreover, as HUVEC express some members of Sph-1-P receptor, 16, 18) it is critical to determine whether compound 5 inhibits these three steps or not. As shown in Table 3 , compound 5 inhibited [6- 3 H]thymidine uptake of Sph-1-P-stimulated HUVEC, and the IC 50 value was 18 nM. This finding indicated that compound 5 suppressed DNA synthesis and the proliferation of HUVEC by antagonizing Sph-1-P receptors, presumably S1P 1 . Compound 5 also inhibited Sph-1-P-induced HUVEC migration with an IC 50 value of 650 nM (Table 3 ). In addition, we checked the effect of compound 5 on the Rac activation of Sph-1-P-stimulated HUVEC because Rac, a Rho family small GTPase, is an essential regulator of Sph-1-P-induced HUVEC migration. 19, 20) The 3 min stimulation of serumstarved HUVEC with 10 nM Sph-1-P activated the Rac, and 7.1 mM of compound 5 completely negated the effect of Sph-1-P (Fig. 1) . These results suggest that compound 5 blocked the Sph-1-P receptors and interrupted the Sph-1-P signaling for the proliferation and migration of vascular endothelial cells. Inhibitory Effect of Compound 5 on HUVEC Tube Formation Next, we confirmed the effect of compound 5 on HUVEC tube formation. In order to exclude the possibility that the compound's toxicity itself brings about the inhibition of tube formation, we concurrently performed a HUVEC tube formation assay and a cytotoxicity assay with the same 48-well plate. After 3 h incubation with or without 1 mM Sph-1-P and various concentrations of compound 5, the conditioned media were used for the cytotoxicity assay and the tubular HUVEC in the same wells were fixed and stained for quantification of the total tube length. Figures 2A-C shows that compound 5 concentration-dependently inhibited the Sph-1-P-provoked HUVEC tube formation with an IC 50 value of 230 nM. In the cytotoxicity assay, 1 mM Sph-1-P activated HUVEC metabolism and elevated the fluorescence intensity of reduced AlamarBlue from 52142Ϯ2338 to 72279Ϯ4875 (Fig. 2D , the right-end and left-end bars, respectively). Compound 5 concentration-dependently inhibited the increase of the fluorescence intensity of Sph-1-Pstimulated HUVEC, but the intensity was never below that of unstimulated HUVEC, at least up to 14.2 mM (Fig. 2D) . These data clearly show that the inhibitory effect of compound 5 on tube formation is based on a blockade of the Sph-1-P receptors and is not due to the compound's cytotoxicity. The 100 nM Sph-1-P was used as a stimulant in both assays. Each compound was added to serum-starved HUVEC, then HUVEC were stimulated with or without 10 nM Sph-1-P for 3 min. The activated Rac and the total Rac in HUVEC lysate were detected by immunoblotting. Lane no. 1, dimethyl sulfoxideϩ80% (v/v) ethanol; no. 2, dimethyl sulfoxideϩ10 nM Sph-1-P; no. 5, 7.1 mM compound 5ϩ10 nM Sph-1-P; no. 10, HUVEC lysate; others, unrelated compoundϩ10 nM Sph-1-P.
Inhibitory Effect of Compounds 1-5 on the Sph-1-P-
Induced Hypotension Finally, we tested the antagonistic activity of compounds 1-5 in vivo. Since Sugiyama et al. 6) showed that i.v. injection of Sph-1-P at a dose of 10 mg/kg brought about a transient decrease of mean blood pressure for 30 s without affecting the heart rate in anesthetized rats, we followed the same procedure. The i.v. injection of 10 mg/kg Sph-1-P caused transient hypotension for 40 s and did not affect the heart rate in anesthetized Sprague-Dawley rats (Fig. 3A) . I.p. pre-administration of 10 mg/kg PTX for 3 d eliminated the effect of Sph-1-P, which indicated this hypotension response was mediated by Gi-coupled receptor, probably S1P 1 and/or S1P 3 (Fig. 3A) . As shown in Fig. 3B,  compounds 1, 3 , and 4 (each 10 mg/kg) inhibited the Sph-1-P-induced hypotension at 3 min, but these antagonistic activities were gradually attenuated. Compound 2 did not show antagonistic activity. On the other hand, compound 5 perfectly prevented hypotension. Figure 3C shows the time course of the antagonistic activity of all the compounds. It was noteworthy that compound 5 completely inhibited Sph-1-P-induced hypotension over 30 min. The dose-dependency test of compound 5 revealed that 10 mg/kg administration of compound 5 showed good reproducibility and it inhibited the hypotension by 100-90% for 30 min (Fig. 3D) . These results show that compound 5 has potent antagonistic activity against in vivo Sph-1-P signaling.
DISCUSSION
By derivatization, S1P 1 antagonist activity of compound 5 as the IC 50 value in the cAMP assay improved and was 150-fold stronger than that of chemical lead 2, from 5.7 mM to 38 nM 12) (Table 1) . Additionally, in the binding assay, the IC 50 value also improved 125-fold, from 25 mM to 200 nM. 12) On the other hand, the S1P 1 specificity of compound 5 among Sph-1-P receptors did not dramatically improve ( Table 2) .
Although there is some difference between the IC 50 values in the cAMP and [
33 P]Sph-1-P/S1P 1 binding assay (38, 200 nM, respectively), this is possibly due to the influence of fatty acid-free bovine serum albumin in the binding assay buffer. The albumin is necessary to suppress the non-specific binding of [
33 P]Sph-1-P, but it also reduces the antagonistic activity of compound 5. The S1P 1 antagonist activity of compound 5 measured with FLIPR was weaker than that in the 1504 Vol. 33, No. 9 Ten milligrams per kilograms of each compound was i.v. administered at 0 min, then 10 mg/kg Sph-1-P was i.v. administered repeatedly at the indicated time points (compound 2, nϭ1; others, nϭ2). The inhibition (%) of each compound against Sph-1-P-induced hypotension was calculated from the minimum blood pressure after each Sph-1-P injection and plotted. The average of minimum blood pressure in a stable state was set at 100% inhibition, whereas the minimum blood pressure after control injection of Sph-1-P was set at 0% inhibition. (D) The dose-dependency of compound 5 on the hypotension test. The 0.1, 1, or 10 mg/kg of compound 5 was i.v. administered. The same experimental and calculation methods described above were used (nϭ3). cAMP assay (Tables 1, 2 ). Not only this compound, but also most derivatives, the IC 50 values against S1P 1 measured with FLIPR tended to be one-figure higher than those in the cAMP assay (data not shown). This may be the influence of Gqi5 chimeric G protein, which is used in FLIPR assay and converts S1P 1 downstream signaling from cAMP to Ca 2ϩ . Compound 5 inhibited S1P 1 the most, with S1P 3 being the next most inhibited among the Sph-1-P receptors (Table 2) . This offers an advantageous opportunity to study the function of Sph-1-P on vascular endothelial cells because both S1P 1 and S1P 3 , 3, 8) especially S1P 1 , 5, 21, 22) are supposed to be important for both the response of vascular endothelial cells, such as HUVEC and neovascularization by Sph-1-P. Indeed, compound 5 could inhibit the proliferation, migration, and tube formation of Sph-1-P-stimulated HUVEC (Table 3 , Fig.  2) . Although a higher concentration of compound 5 was needed compared to S1P 1 -expressing cells, this may be due to HUVEC express multiple Sph-1-P receptors. 16, 18) In these three assays, the incubation time of compound 5 with HUVEC was 31, 4, and 3 h, respectively. Longer incubation in [6- 3 H]thymidine uptake assay may bring about a stronger inhibitory effect than the other two assays. In addition, because the incubation time for the tube formation assay is 3 h, it is thought that migration rather than proliferation is important for the formation of the HUVEC capillary network. Therefore, it is a reasonable result that IC 50 values in the migration and tube formation assay (650, 230 nM, respectively) were close.
Compound 5 inhibited Sph-1-P-induced transient hypotension in Sprague-Dawley rats (Figs. 3C, D) . A previous report showed that Sph-1-P dose-dependently induced transient relaxation of rat mesenteric arterioles via activation of the endothelial isoform of nitric oxide synthase with an EC 50 value of 10Ϯ3 nM. 23) Therefore, in our rat study, the i.v. injection of Sph-1-P probably caused direct vasorelaxation and resulted in transient hypotension. Taking these findings together, it was demonstrated that compound 5 prevented Sph-1-P-induced vasorelaxation and hypotension mainly by blocking S1P 1 and/or S1P 3 on the vascular endothelial cells of the rats, although the precise mechanism must be investigated in the future. There are some differences of the inhibitory effect of compounds in the cAMP assay and the hypotension test. The IC 50 values of compounds 1 and 2 in the cAMP assay were equivalent (200, 220 nM, respectively); however, compound 2 was ineffective in the hypotension test (Fig. 3C) . Similarly, The IC 50 values of compounds 3, 4, and 5 in the cAMP assay were also equivalent (54, 49, 38 nM, respectively); however, compound 5 showed strong inhibition in the hypotension test (Figs. 3C, D) . The most possible reason is the difference of solubility of compounds. Compounds 1 and 5 are easily dissolved in distilled water, but the solubility of other compounds is inferior. It may cause the difference of plasma concentration of compounds. Another possible reason might be the difference of the stability of compounds in rat plasma.
In conclusion, the S1P 1 -directional antagonist compound 5 inhibited the biological responses of HUVEC induced by Sph-1-P, i.e., proliferation, migration, and tube formation. Moreover, it showed a potent inhibitory effect on Sph-1-Pinduced hypotension in rats. Compound 5 will be a useful tool to analyze the in vivo effect of Sph-1-P, especially on vascular endothelial cells.
